Elder Drugs & Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 131.44%
- Profit Growth 187.21%
- Ebitda 171.97%
- Net Worth 149.13%
- Total Assets 25.44%
About Elder Drugs & Pharmaceutical
Elder Drugs & Pharmaceutical Private Limited (EDPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 18 February 2020 (Four years and 11 months 26 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Geeta, Rahul Palod, and Suraj serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909DL2020PTC362050
-
Company No.
362050
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Feb 2020
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Elder Drugs & Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Geeta
|
Director | 18-Feb-2020 | Current |
|
Rahul Palod
|
Director | 18-Feb-2020 | Current |
|
Suraj
|
Director | 10-May-2024 | Current |
Financial Performance of Elder Drugs & Pharmaceutical.
Elder Drugs & Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 131.44% increase. The company also saw a substantial improvement in profitability, with a 187.21% increase in profit. The company's net worth Soared by an impressive increase of 149.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elder Drugs & Pharmaceutical?
In 2022, Elder Drugs & Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sonkei Pharmaceuticals LlpSuraj is a mutual person
-
Exalenz Pharma Private Limited
Suraj is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elder Drugs & Pharmaceutical?
Unlock and access historical data on people associated with Elder Drugs & Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elder Drugs & Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elder Drugs & Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
